Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788017 | 0.86 | NFKB1 (0.36) | P2RX7NFKB1NFKB2RELAABCB1 | |
| SCHEMBL760600 | 0.80 | GLA (0.40) | NFKB1NFKB2RELA | |
| SCHEMBL4077274 | 0.79 | ECE1 (0.34) | P2RX7NFKB1NFKB2RELA | |
| SCHEMBL12488873 | 0.77 | P2RX7 (0.34) | P2RX7NFKB1NFKB2RELASRD5A1 | |
| SCHEMBL3343887 | 0.68 | P2RX7 (0.52) | P2RX7NFKB1NFKB2RELAMEN1 | |
| SCHEMBL9138384 | 0.66 | NFKB1 (0.41) | P2RX7NFKB1NFKB2RELANPC1 | |
| SCHEMBL19765489 | 0.66 | NOTUM (0.35) | P2RX7NFKB1NFKB2RELAABCB1 | |
| SCHEMBL16400796 | 0.65 | P2RX7 (0.46) | P2RX7MEN1KMT2A | |
| SCHEMBL3341987 | 0.65 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL3347368 | 0.65 | P2RX7 (0.43) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049517-B1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| CN-101370776-A | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARM INC (US) | 2009-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286790-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | P2RX7 2641/4885NFKB1 2700/4885NFKB2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.